Crane and Sasisekharan Make It a Trifecta

I had Tempo Pharmaceticals CEO (and Polaris Ventures partner) Alan Crane on a panel this past Wednesday night at one of the occasional Convergence Forum dinners at the Harvard Faculty Club.

Earlier in the week, Ryan McBride of Mass HIgh Tech had noted that Crane was involved in a new start-up called Parasol Therapeutics. This is the third company that Crane, MIT prof Ram Sasisekharan, and Polaris have started (#1 was Momenta Pharmaceuticals, now public; #2 was Tempo.)

Crane just smiled when I asked him about Parasol, which also involves Polaris principal Kevin Bitterman. He said the company is still very much in stealth mode, and that he's just serving as a director -- no plans to leave Tempo and serve as Parasol's CEO.